Walgreens Boots Alliance, Inc. (WBA) FCF Payout Ratio: N/A
The FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA) is N/A.
WBA FCF Payout Ratio Chart
WBA Average FCF Payout Ratio Chart
WBA FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
FCF PAYOUT RATIO AVG TTM
57.67%
FCF PAYOUT RATIO AVG 3Y
50.02%
FCF PAYOUT RATIO AVG 5Y
42.14%
FCF PAYOUT RATIO AVG 10Y
37.47%
FCF PAYOUT RATIO AVG 15Y
36.22%
FCF PAYOUT RATIO AVG 20Y
39.89%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Payout Ratio Comparison
FCF Payout Ratio
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
5.60%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2024 | ($363.00M) | $1.26B | N/A (Loss) |
| 2023 | $141.00M | $1.66B | n/m |
| 2022 | $2.17B | $1.66B | 76.6% |
| 2021 | $4.18B | $1.62B | 38.7% |
| 2020 | $4.11B | $1.75B | 42.5% |
| 2019 | $3.89B | $1.64B | 42.2% |
| 2018 | $6.90B | $1.74B | 25.2% |
| 2017 | $5.90B | $1.63B | 27.5% |
| 2016 | $6.52B | $1.56B | 24.0% |
| 2015 | $4.41B | $1.38B | 31.4% |
| 2014 | $2.79B | $1.20B | 43.0% |
| 2013 | $3.09B | $1.04B | 33.7% |
| 2012 | $2.88B | $787.00M | 27.3% |
| 2011 | $2.43B | $647.00M | 26.6% |
| 2010 | $2.73B | $541.00M | 19.8% |
| 2009 | $2.18B | $446.00M | 20.4% |
| 2008 | $814.00M | $376.00M | 46.2% |
| 2007 | $571.40M | $310.20M | 54.3% |
| 2006 | $1.10B | $262.90M | 23.9% |
| 2005 | $133.70M | $214.50M | 160.4% |
| 2004 | $713.20M | $176.90M | 24.8% |
| 2003 | $696.40M | $152.40M | 21.9% |
| 2002 | $539.40M | $147.00M | 27.3% |
| 2001 | ($517.80M) | $140.90M | N/A (Loss) |
| 2000 | ($147.40M) | $134.60M | N/A (Loss) |
| 1999 | ($71.10M) | $128.60M | N/A (Loss) |
| 1998 | ($70.00M) | $123.00M | N/A (Loss) |
| 1997 | $165.00M | $116.00M | 70.3% |
| 1996 | $46.70M | $105.20M | 225.3% |
| 1995 | $34.70M | $92.90M | 267.7% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Walgreens Boots Alliance, Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Walgreens Boots Alliance, Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The FCF payout ratio for WBA stock is N/A.
- What is the TTM average FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The TTM average FCF payout ratio for WBA stock is 57.67%.
- What is the 3Y average FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The 3Y average FCF payout ratio for WBA stock is 50.02%.
- What is the 5Y average FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The 5Y average FCF payout ratio for WBA stock is 42.14%.
- What is the 10Y average FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The 10Y average FCF payout ratio for WBA stock is 37.47%.
- What is the 15Y average FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The 15Y average FCF payout ratio for WBA stock is 36.22%.
- What is the 20Y average FCF payout ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The 20Y average FCF payout ratio for WBA stock is 39.89%.
Walgreens Boots Alliance, Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2022-08-31 | 76.63% |
| 2021-08-31 | 38.72% |
| 2020-08-31 | 42.51% |
| 2019-08-31 | 42.21% |
| 2018-08-31 | 25.21% |
| 2017-08-31 | 27.54% |
| 2016-08-31 | 23.97% |
| 2015-08-31 | 31.36% |
| 2014-08-31 | 43.02% |
| 2013-08-31 | 33.67% |
| 2012-08-31 | 27.32% |
| 2011-08-31 | 26.63% |
| 2010-08-31 | 19.82% |
| 2009-08-31 | 20.42% |
| 2008-08-31 | 46.19% |
| 2007-08-31 | 54.29% |
| 2006-08-31 | 23.86% |
| 2005-08-31 | 160.43% |
| 2004-08-31 | 24.80% |
| 2003-08-31 | 21.88% |
| 2002-08-31 | 27.25% |
| 1997-08-31 | 70.30% |
| 1996-08-31 | 225.27% |
| 1995-08-31 | 267.72% |
About Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc., established in 1901 and based in Deerfield, Illinois, operates as a leading global retailer focused on pharmacy, health, and beauty products. Its business activities are organized into two primary divisions: the United States and International. In the United States, the company dispenses prescription drugs and offers a diverse selection of retail goods. This includes items for health, wellness, beauty, and personal care, alongside general merchandise and consumable products, all available through its extensive network of retail drugstores. The U.S. segment also provides specialized central pharmacy services and mail delivery options for prescriptions. As of August 31, 2021, this division managed 8,965 retail outlets under the Walgreens and Duane Reade banners, complemented by five specialty pharmacies. The International segment focuses on the sale of prescription medications, health and wellness items, beauty products, personal care essentials, and other consumer goods. These are sold through its pharmacy-centric health and beauty retail locations, optical practices, its online platform boots.com, and an integrated mobile application. Additionally, this segment engages in pharmaceutical wholesale and distribution operations within Germany. By August 31, 2021, the international portfolio included 4,031 retail stores operating under brands such as Boots, Benavides, and Ahumada, located across countries including the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile. It also oversaw 548 optical practices, with 160 of these operating as franchises.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Timothy C. Wentworth